Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Fmr LLC

FMR LLC cut its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 6.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,209,436 shares of the company's stock after selling 228,450 shares during the period. FMR LLC owned 0.65% of Elanco Animal Health worth $47,147,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the business. The Manufacturers Life Insurance Company lifted its stake in shares of Elanco Animal Health by 6.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 6,385,467 shares of the company's stock valued at $93,803,000 after purchasing an additional 394,921 shares during the period. Qsemble Capital Management LP acquired a new position in Elanco Animal Health during the third quarter worth $264,000. Bank of Montreal Can raised its position in Elanco Animal Health by 3.5% during the third quarter. Bank of Montreal Can now owns 416,336 shares of the company's stock worth $5,962,000 after acquiring an additional 14,190 shares during the period. Jennison Associates LLC raised its position in Elanco Animal Health by 70.9% during the third quarter. Jennison Associates LLC now owns 1,080,464 shares of the company's stock worth $15,872,000 after acquiring an additional 448,368 shares during the period. Finally, Commerce Bank raised its position in Elanco Animal Health by 2.2% during the third quarter. Commerce Bank now owns 35,114 shares of the company's stock worth $516,000 after acquiring an additional 741 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Trading Up 3.1 %

Shares of ELAN traded up $0.38 during mid-day trading on Friday, reaching $12.50. The stock had a trading volume of 4,585,191 shares, compared to its average volume of 4,551,213. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The firm has a market cap of $6.18 billion, a price-to-earnings ratio of 31.25, a P/E/G ratio of 1.98 and a beta of 1.41. The business's fifty day moving average is $13.43 and its 200 day moving average is $14.47. Elanco Animal Health Incorporated has a 52-week low of $11.40 and a 52-week high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.01. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. Elanco Animal Health's revenue was down 3.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.18 earnings per share. On average, sell-side analysts predict that Elanco Animal Health Incorporated will post 0.92 EPS for the current fiscal year.

Analysts Set New Price Targets

ELAN has been the subject of a number of research reports. Barclays upped their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an "overweight" rating in a report on Friday, November 8th. Leerink Partners initiated coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They set a "market perform" rating and a $14.00 target price for the company. Morgan Stanley lowered shares of Elanco Animal Health from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $17.00 to $15.00 in a report on Thursday, September 19th. Stifel Nicolaus reaffirmed a "buy" rating and set a $20.00 target price on shares of Elanco Animal Health in a report on Thursday, September 19th. Finally, Leerink Partnrs raised shares of Elanco Animal Health to a "hold" rating in a report on Monday, December 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $16.57.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.